Denali Therapeutics’ (DNLI) Buy Rating Reiterated at B. Riley
B. Riley restated their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $35.00 price objective on the stock, down from their prior price objective of $38.00. B. Riley also issued estimates for Denali Therapeutics’ Q2 2025 earnings at ($0.80) EPS, […]
B. Riley restated their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $35.00 price objective on the stock, down from their prior price objective of $38.00. B. Riley also issued estimates for Denali Therapeutics’ Q2 2025 earnings at ($0.80) EPS, […]
